Medicare increases payments for oncology infusion and begins a one-year demonstration project that pays oncologists to assess the side effects of chemotherapy.
CMS also decided to cover off-label uses of approved colorectal cancer drugs in clinical trials, and allowed broader use of PET scans.
Also Unclear whether HHS Secretary Tommy Thompson will depart as previously planned.
California approves $3 billion program for stem-cell research.
Oklahoma’s new cigarette tax will provide $7 million a year to the University of Oklahoma Cancer Center.
National Cancer Policy Board will end in 2005, NCI to support a cancer forum at IOM.
Funding opportunities listed.
October issue of Business & Regulatory Report included.
Trending Stories
- Right-wing provocateur Laura Loomer comes for FDA’s Vinay Prasad
- U.S. News & World Report expands evaluation of outcomes in cancer subspecialties
- GOP-led Congress rejects Trump’s plans to gut medical research
Senate bill gives NIH a $400 million raise - FY25 paylines drop to 4th percentile—a historic low—as NCI braces for Trump’s FY26 budget cuts
- Vinay Prasad falls from grace at FDA upon flunking Trump political purity test
MAHA leaders agree on one point: COVID was mishandled. Is that enough to run science-based agencies? - Oncologist biotech entrepreneur George Tidmarsh joins FDA as CDER director
His appointment came out of “proximity” to Makary and Bhattacharya
